These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2643685)

  • 1. Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
    Barba D; Saris SC; Holder C; Rosenberg SA; Oldfield EH
    J Neurosurg; 1989 Feb; 70(2):175-82. PubMed ID: 2643685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adoptive immunotherapy in patients with malignant glioma].
    Yoshida S; Takai N; Saito T; Tanaka R
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1930-2. PubMed ID: 3496052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.
    Sankhla SK; Nadkarni JS; Bhagwati SN
    J Neurooncol; 1996 Feb; 27(2):133-40. PubMed ID: 8699235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
    Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
    Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.
    Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
    J Neurosurg; 1986 May; 64(5):743-9. PubMed ID: 3517250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.
    Shimizu K; Okamoto Y; Miyao Y; Yamada M; Ushio Y; Hayakawa T; Ikeda H; Mogami H
    J Neurosurg; 1987 Apr; 66(4):519-21. PubMed ID: 3494108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental studies on the treatment of recurrent gliomas].
    Yamada M; Shimizu K; Okamoto Y; Miyao Y; Matsui Y; Tsuda N; Mogami H
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1890-5. PubMed ID: 3496051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
    Merchant RE; Grant AJ; Merchant LH; Young HF
    Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
    Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
    No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor.
    Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
    Radiat Med; 1988; 6(6):276-81. PubMed ID: 2854899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of malignant tumors by interleukin 2 and LAK cells].
    Degos L
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):119-22. PubMed ID: 3260373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
    Jacobs SK; Wilson DJ; Melin G; Parham CW; Holcomb B; Kornblith PL; Grimm EA
    Neurol Res; 1986 Jun; 8(2):81-7. PubMed ID: 2875409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
    Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LAK cells and cancer].
    Taguchi T; Kimoto Y
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.